Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we sprint through measles—one of the most contagious infectious diseases known—covering transmission, classic clinical presentation, complications, diagnosis, and prevention through vaccination.
We start with the big picture. Measles (rubeola) is a highly contagious viral illness caused by a paramyxovirus and remains a major global public health concern despite the availability of an effective vaccine. Clinically, the disease is defined by fever, cough, coryza, conjunctivitis, and a characteristic maculopapular rash.
After decades of progress toward elimination, measles has resurged worldwide. Global cases increased dramatically from about 132,000 cases in 2016 to nearly 870,000 in 2019, driven by large outbreaks and declining vaccination coverage. Pandemic-related disruptions to immunization programs worsened the problem, with global first-dose vaccine coverage dropping to 81% in 2021—the lowest level in more than a decade. Even in the United States, outbreaks continue to occur, with the vast majority of cases seen in unvaccinated individuals or those with unknown vaccination status.
The reason measles spreads so easily is its extraordinary transmissibility. The virus spreads through airborne respiratory droplets, and viral particles can remain suspended in the air for up to two hours after an infected person leaves the area. The basic reproduction number (R₀) is estimated at 12–18, meaning a single infected person can transmit the virus to more than a dozen susceptible individuals.
The incubation period is typically 10–14 days, and patients become contagious about four days before the rash appears and remain infectious until four days after rash onset. Because measles spreads so efficiently, achieving herd immunity requires at least 95% vaccine coverage with two doses.
Clinically, measles follows a predictable three-phase course.
First is the prodromal phase, lasting about 2–4 days. Patients develop high fever along with the “three Cs”: cough, coryza, and conjunctivitis. A key diagnostic clue during this phase is the appearance of Koplik spots—small bluish-white lesions on the buccal mucosa, which are considered pathognomonic and typically appear 1–2 days before the rash.
Next comes the exanthem phase, when the classic erythematous maculopapular rash appears. The rash begins on the face and hairline, then spreads downward to the trunk and extremities over several days. It often becomes confluent on the face and upper body before gradually fading in the same order that it appeared.
The final stage is the convalescent phase, during which symptoms gradually resolve, typically within about one week after rash onset in uncomplicated cases.
Despite this classic presentation, measles is far from benign. Approximately 30–40% of patients develop complications, particularly among infants, adults, pregnant individuals, immunocompromised patients, and malnourished children.
Common complications include:• Otitis media (about 7–9% of cases)• Pneumonia, the leading cause of measles-related death• Diarrhea and dehydration
More severe complications involve the central nervous system. Acute postinfectious encephalitis occurs in roughly 1 in 1,000 cases and carries a 20% mortality rate. Immunocompromised patients may develop measles inclusion-body encephalitis, which is nearly always fatal.
One of the most devastating complications is subacute sclerosing panencephalitis (SSPE)—a progressive degenerative brain disease that develops 7–10 years after infection. Although rare, it is universally fatal within several years of onset.
Measles also produces a phenomenon known as immune amnesia. The virus suppresses immune memory for 2–3 years, increasing vulnerability to other infections and contributing to excess mortality even after recovery from the acute illness.
Diagnosis is often suspected clinically when patients present with fever, rash, and the three Cs, especially if Koplik spots are observed. However, laboratory confirmation is essential—particularly during outbreaks or in previously vaccinated individuals who may develop modified measles with milder symptoms.
Diagnostic testing includes:• RT-PCR detection of viral RNA• Measles IgM serology using ELISA• Viral genotyping for epidemiologic surveillance
Management of measles is primarily supportive, as no specific antiviral therapy exists. Treatment focuses on hydration, fever control, nutritional support, and treatment of secondary bacterial infections.
One intervention with strong evidence is vitamin A supplementation. Clinical trials have demonstrated that vitamin A significantly reduces measles-related mortality, particularly in children. Current recommendations are to administer two age-adjusted doses of vitamin A on consecutive days, with an additional dose given later if vitamin A deficiency is suspected.
Ultimately, the most effective strategy against measles is prevention through vaccination. The MMR vaccine provides highly effective protection, with two doses achieving approximately 97% immunity.
We close with the key clinical takeaways:
• Measles is among the most contagious infectious diseases known• The classic presentation includes fever, cough, coryza, conjunctivitis, Koplik spots, and a descending maculopapular rash• Complications occur in up to 40% of cases and can include pneumonia and encephalitis• Vitamin A supplementation significantly reduces mortality in children• Maintaining ≥95% vaccination coverage is essential for herd immunity
Measles is often viewed as a childhood disease of the past—but as vaccination rates decline in some regions, clinicians must remain vigilant. Recognizing measles quickly, isolating cases, and promoting vaccination remain essential tools for preventing outbreaks and protecting vulnerable populations.

In this episode of Hospital Medicine Unplugged, we sprint through aplastic anemia—recognize the pancytopenia, confirm marrow failure, suppress the immune attack, and watch for clonal evolution.
We open with the diagnostic framework that defines disease severity. The Camitta criteria remain the standard classification. Severe aplastic anemia requires bone marrow cellularity <25% plus at least two of three cytopenias:• ANC <500/μL• Platelets <20,000/μL• Reticulocytes <60,000/μL
Very severe disease is defined by ANC <200/μL, a group at extremely high infection risk. These criteria matter because treatment decisions hinge on severity, patient age, and donor availability.
Next, we unpack the pathophysiology—the immune system attacking hematopoiesis. In acquired aplastic anemia, cytotoxic T cells target hematopoietic stem and progenitor cells (HSPCs). These T cells release interferon-γ and TNF-α, which activate Fas/Fas-ligand pathways, triggering apoptosis of stem cells and collapsing bone marrow production.
Recent discoveries explain how immune escape and clonal selection occur. IFN-γ suppresses HSPCs expressing HLA class I molecules, while HLA-deficient clones evade immune destruction, creating a survival advantage in about 30% of patients. Meanwhile, regulatory T cells are decreased, and their restoration often parallels hematologic recovery.
Then comes one of the biggest therapeutic advances in decades: adding eltrombopag to immunosuppressive therapy. Standard treatment has long been horse antithymocyte globulin (ATG) plus cyclosporine, but the RACE trial changed the landscape.
When eltrombopag was added:• Complete response at 3 months doubled (22% vs 10%)• Overall response at 6 months increased to 68% vs 41%• Median time to response shortened from 8.8 months to 3 months
Because of these results, ASH 2025 guidelines now recommend eltrombopag alongside ATG and cyclosporine for severe and very severe aplastic anemia in both adults and children. Beyond thrombopoiesis, eltrombopag appears to stimulate stem-cell recovery and counteract IFN-γ–mediated suppression.
For curative therapy, we turn to hematopoietic stem cell transplantation. Modern guidelines use age-based decision pathways:
• <20 years: matched sibling transplant or immunosuppressive therapy• 20–40 years: matched unrelated donor transplant or immunosuppressive therapy• >40 years: immunosuppressive therapy preferred
Haploidentical transplant is generally reserved for later lines, with immunosuppressive therapy favored initially.
Another hallmark of aplastic anemia is its relationship with paroxysmal nocturnal hemoglobinuria (PNH). Up to 50% of patients harbor a PNH clone, detectable by FLAER-based flow cytometry with CD55/CD59 testing. Importantly, the presence of a PNH clone is actually a favorable prognostic sign.
Patients with PNH clones show:• Better response to immunosuppressive therapy (≈78% vs 50%)• Better transplant outcomes (≈97% vs 77%)• Lower risk of progression to myelodysplastic syndrome
The mechanism is elegant: GPI-negative stem cells with PIGA mutations escape immune destruction, allowing them to survive when normal HSPCs are targeted.
Despite improved survival, long-term complications remain a major concern. About 10–20% of patients develop clonal evolution to myelodysplastic syndrome or acute myeloid leukemia within 10 years, particularly after immunosuppressive therapy.
Genomic studies show clonal hematopoiesis in roughly half of patients, with mutation patterns predicting outcomes:• DNMT3A and ASXL1 → higher risk of clonal expansion and progression to MDS/AML• BCOR, BCORL1, and PIGA → better response and more stable disease
Risk factors for clonal evolution include older age, poor response to immunosuppressive therapy, high-risk mutations, and multiple mutations with higher allele burden.
When secondary myeloid malignancies occur, they often carry high-risk cytogenetics such as monosomy 7 or complex karyotypes, with ~40% five-year survival without transplant. Fortunately, allogeneic stem cell transplantation can improve survival to about 64%.
The big picture today is far more optimistic than in the past. With modern therapy—including ATG, cyclosporine, and eltrombopag—five-year survival now exceeds 80%, with some studies reporting survival approaching 97%. But relapse still occurs in about 22% of patients, making long-term monitoring essential.
We close with the system moves: confirm severe disease using Camitta criteria, suppress the immune attack with ATG + cyclosporine + eltrombopag, evaluate for transplant based on age and donor availability, screen all patients for PNH clones, and monitor closely for clonal evolution.
Aplastic anemia is no longer uniformly fatal—but recognizing the immune mechanism, treating early, and tracking clonal risk can transform outcomes for these patients.

In this episode of Hospital Medicine Unplugged, we sprint through Brugada syndrome—spot the ECG, stratify the risk, prevent sudden cardiac death, and avoid the triggers that unmask malignant arrhythmias.
We start with the ECG that makes the diagnosis. Type 1 Brugada pattern is the only diagnostic finding: coved ST elevation ≥2 mm in ≥1 right precordial lead (V1–V3) followed by a negative T wave. The 2013 consensus simplified the diagnosis—a Type 1 pattern alone (spontaneous or drug-induced) is sufficient, without requiring symptoms or family history. Type 2 (“saddleback”) pattern shows ≥0.5 mm ST elevation with a convex ST segment and positive T wave, but it is only suggestive, not diagnostic.
Next comes a critical inpatient pearl: Brugada ECG patterns are dynamic. They may appear and disappear and are often unmasked by fever, sodium-channel blockers, increased vagal tone, or post-prandial states. This is why hospitalized patients with unexplained syncope or fever should have careful ECG review—the pattern may only be visible transiently.
Risk stratification drives management and ICD decisions, which is one of the hardest parts of Brugada care.
High-risk patients (Class I indication for ICD):• Prior cardiac arrest or documented sustained ventricular arrhythmia• Spontaneous Type 1 ECG with syncope presumed due to ventricular arrhythmia
These patients face annual event rates of roughly 5–10%, making ICD therapy life-saving.
Intermediate risk:• Asymptomatic spontaneous Type 1 pattern (≈0.5–1.2% annual risk)• Syncope with spontaneous Type 1 pattern (≈6–19% event risk over ~2–3 years)• Fever-induced Type 1 ECG pattern
Low risk (ICD not indicated):• Asymptomatic patients with only drug-induced Type 1 pattern• Event rate <0.5% annually
A key myth to bust: family history alone does NOT reliably predict individual arrhythmic risk.
We also review BRUGADA-RISK, a modern clinical risk model incorporating ECG and clinical variables to estimate 5-year arrhythmic risk, showing strong predictive performance with ~71% sensitivity and ~80% specificity at a 10% risk threshold.
Then comes the debate over electrophysiology studies (EPS). Current guidelines give Class IIb support for programmed ventricular stimulation in asymptomatic patients with spontaneous Type 1 ECG. Inducible arrhythmias roughly double the risk of events, but the absence of inducibility does not guarantee safety, so clinical history still matters most.
When prevention matters most, remember the bottom line: ICD implantation is the only proven therapy that prevents sudden cardiac death in Brugada syndrome.
Class I indications for ICD:• Survivors of cardiac arrest• Documented spontaneous sustained VT• Spontaneous Type 1 ECG with arrhythmic syncope
For patients with recurrent ICD shocks, escalation strategies include quinidine therapy or catheter ablation targeting abnormal epicardial substrate in the RV outflow tract.
Hospital teams must also know the medications that worsen Brugada. Drugs that block cardiac sodium channels can unmask the ECG pattern and trigger ventricular arrhythmias. High-risk categories include Class IC antiarrhythmics (flecainide, propafenone), tricyclic antidepressants, lithium, certain antipsychotics, local anesthetics like bupivacaine, propofol, cocaine, and excessive alcohol. The safest move is to check brugadadrugs.org before prescribing.
Finally, one of the most important bedside pearls: fever is a powerful arrhythmic trigger in Brugada syndrome. Temperature-dependent sodium channel dysfunction can convert a silent patient into a ventricular arrhythmia emergency. That’s why aggressive antipyretic therapy is mandatory in any febrile Brugada patient—especially in children and hospitalized patients.
We close with the take-home system moves: recognize the Type 1 ECG pattern, treat fever aggressively, avoid sodium-channel-blocking medications, risk-stratify carefully, and implant ICDs in the right patients.
Brugada syndrome may hide in plain sight—but once you know the ECG and the triggers, you can identify risk early and prevent sudden cardiac death.

In this episode of Hospital Medicine Unplugged, we tackle one of the most ethically charged and clinically challenging topics in inpatient care: the use of restraints in the hospital setting. When are restraints justified, why do we still use them so often, and what does the evidence actually show about benefit versus harm?
We start by defining physical restraints—any device or method that limits a patient’s movement, from wrist and ankle restraints to vests, belts, bed rails, and enclosure beds—and chemical restraints, medications used primarily to control behavior rather than treat an underlying condition. We unpack why experts increasingly reject the term “chemical restraint,” emphasizing pharmacologic treatment of agitation aimed at calming, not sedating, patients while addressing root causes.
Next, we explore why restraints are used: fall prevention, prevention of device removal, management of delirium or agitation, and protection of staff. But here’s the paradox—observational data consistently show higher rates of the very outcomes restraints are meant to prevent, including unplanned extubations, device removal, increased agitation, delirium, and longer ICU stays.
We break down the scope of the problem. Nearly 1 in 10 hospitalized patients experiences restraint use, with rates approaching 40% of ICU encounters and even higher among mechanically ventilated patients. Use varies widely by setting, staffing, and culture—highlighting that restraint use is often system-driven, not patient-driven.
The heart of the episode focuses on ethics and law. Restraints represent a profound restriction of liberty, and ethical use requires three conditions: medical appropriateness, informed consent (or a valid emergency exception), and use of the least restrictive option. We review federal regulatory requirements—restraints only for imminent harm, after less restrictive measures fail, time-limited orders, mandatory face-to-face evaluations, continuous monitoring, and early removal.
We then confront the real harms. Physically: DVT, PE, aspiration pneumonia, fractures, pressure injuries, rhabdomyolysis, asphyxiation, and death. Psychologically: fear, loss of dignity, and PTSD, affecting up to 25–47% of patients after a restraint event. These risks rise with each additional day of restraint use.
From there, we pivot to what actually works: alternatives. Multicomponent, non-pharmacologic strategies—reorientation, sleep hygiene, pain control, early mobility, family engagement, sitters, sensory optimization, and delirium prevention bundles like ABCDEF—reduce delirium and restraint use by 40–60% while improving outcomes.
We close with practical takeaways: assess underlying causes first (pain, hypoxia, infection, withdrawal, delirium), use verbal de-escalation and environment before meds, reserve restraints for true emergencies, document meticulously, reassess relentlessly, and remove early. The bottom line: restraints are not benign, not preventive, and not routine care—they are a last resort in modern, patient-centered hospital medicine.
Fast, evidence-driven, and ethically grounded—protect safety without sacrificing dignity.

In this episode of Hospital Medicine Unplugged, we tackle dementia with behavioral and psychological symptoms (BPSD) in the hospitalized patient—why it happens, how to assess it fast, and how to manage it safely without making things worse.
We start with the big picture: BPSD affects >90% of people with dementia, often driving hospital admissions. Symptoms span agitation, aggression, psychosis, depression, anxiety, apathy, sleep disturbance, and disinhibition—and they’re not benign. In the hospital, BPSD is linked to longer stays, higher mortality, restraint use, staff injury, early institutionalization, and one-third of total dementia care costs.
Next, we walk through the do-first inpatient assessment. Rule out delirium (acute onset, fluctuating attention), then hunt for reversible triggers: pain, constipation, urinary retention, infection, hypoxia, metabolic derangements, sleep disruption, and iatrogenic harm from polypharmacy—especially anticholinergics, benzodiazepines, and opioids. Collateral history is critical to establish baseline behavior. Use structured tools like CAM/4AT for delirium, PAINAD for nonverbal pain, and NPI or CMAI to quantify symptoms. The DICE approach (Describe–Investigate–Create–Evaluate) keeps management personalized and efficient.
We emphasize that non-pharmacologic strategies are first-line—always. In the hospital, this means person-centered care: reorientation, sleep hygiene, early mobility, sensory optimization (glasses/hearing aids), hydration, toileting, nutrition, and calm communication. Caregiver- and staff-focused interventions have the strongest evidence, reducing both symptom burden and distress. Music therapy, tailored activities, exercise, massage/touch, and multicomponent delirium programs like HELP can meaningfully reduce agitation and prevent escalation.
When symptoms threaten safety, we cover how to use meds sparingly and smartly. Before adding anything, do a medication cleanup. Pharmacotherapy is time-limited, lowest dose, shortest duration, and always paired with non-drug strategies.• Cholinesterase inhibitors can modestly improve BPSD over time.• Antipsychotics offer small benefits for severe agitation or psychosis but carry real risks—increased mortality, stroke, sedation, EPS, QT prolongation, and functional decline. No clear winner among agents. Use hours to days, reassess daily, and document risk–benefit discussions. Avoid dopamine blockers in Lewy body dementia; if unavoidable, extreme caution.• SSRIs help depression/anxiety; evidence for agitation is limited. Mirtazapine doesn’t help agitation.• Benzodiazepines and valproate are generally avoid.• Pain control matters—untreated pain fuels agitation.
We close with hospital pearls: no routine drugs for delirium; antipsychotics only for dangerous behaviors refractory to non-drug care. Plan early for deprescribing—one-third of patients started on antipsychotics in the hospital leave on them unless you stop it. At discharge, communicate what worked: triggers, de-escalation strategies, sleep plans, toileting schedules, and a clear reassessment plan. Align care with goals, dignity, and function.
Bottom line: Treat the cause, lead with non-pharmacologic care, reserve meds for safety, reassess relentlessly, and deprescribe early.

In this episode of Hospital Medicine Unplugged, we tackle one of the most anxiety-provoking inpatient consults: acute facial weakness—Bell’s palsy or stroke? We break down how to tell them apart fast, why the distinction matters, and how to manage each safely in hospitalized patients.
We start with the bedside exam that saves lives. Forehead involvement = peripheral (Bell’s palsy); forehead sparing = central (stroke)—until proven otherwise. Bell’s palsy presents with acute unilateral facial paralysis involving the forehead, often peaking within 72 hours, and may include post-auricular pain, altered taste, hyperacusis, or dry eye, without other neurologic deficits. Stroke typically hits suddenly, often spares the forehead, and comes with red flags like limb weakness, aphasia, gaze deviation, dysphagia, or altered mental status.
We walk through the don’t-miss pitfalls: brainstem strokes that mimic a lower motor neuron pattern, bilateral facial weakness, gradual or progressive onset, recurrent ipsilateral palsy, hearing loss or vertigo, and facial palsy in post-op, ICU, immunocompromised, or cancer patients—all of which demand a lower threshold for imaging and expanded workup.
Next, the inpatient diagnostic strategy. Suspect stroke? Activate the stroke alert—determine last known well, check glucose, perform a focused neuro exam, and get emergent CT/MRI. For classic Bell’s palsy, routine labs and imaging aren’t required, but in hospitalized patients consider MRI with contrast or CSF if there are atypical features, infection risk, multiple cranial nerves involved, or no improvement by 3–6 weeks.
Treatment pearls you can use today:Bell’s palsy—start oral corticosteroids within 72 hours (prednisone 50–60 mg daily x5 days, then taper). This improves complete recovery (NNT ≈10). Antivirals alone don’t work; adding them to steroids may modestly reduce synkinesis, especially in severe paralysis. Eye protection is non-negotiable: artificial tears, nighttime ointment, and a moisture shield—early ophthalmology if exposure risk.Stroke—time is brain. Eligible patients get IV thrombolysis and/or mechanical thrombectomy based on time and imaging, with guideline-directed blood pressure control, antithrombotics, and early rehab.
We close with prognosis and counseling. Bell’s palsy has a 70–85% complete recovery rate (higher with early steroids), but 25–40% may have residual weakness or synkinesis—plan follow-up at 3 months if recovery lags. Stroke outcomes hinge on severity and speed to reperfusion, making rapid recognition critical.
Bottom line: Examine the forehead, hunt for red flags, image early when in doubt, protect the eye, treat fast, and never miss a stroke.

In this episode of Hospital Medicine Unplugged, we get practical about single vs dual antiplatelet therapy after ischemic stroke—who gets what, for how long, and when DAPT does more harm than good.
We start by framing the landscape: noncardioembolic vs cardioembolic stroke, small-vessel vs large-artery disease, and why platelets are center stage in atherothrombotic stroke but not in AF-driven cardioembolism.
Then we walk through who actually qualifies for DAPT:
Minor noncardioembolic ischemic stroke (NIHSS ≤3)
High-risk TIA (ABCD² ≥4)
Select mild-to-moderate strokes (up to NIHSS 5) and large-artery atherosclerosis / intracranial stenosis, where data for intensified therapy are emerging.
We lay out exact protocols you can copy into your order sets:
Classic aspirin + clopidogrel: loading, maintenance, and how to transition cleanly to SAPT.
Ticagrelor + aspirin: when to prefer it (e.g., CYP2C19 loss-of-function) and how to factor in the higher bleeding signal.
Why triple therapy is a hard no.
A big chunk of the episode is “how long is long enough?”:
Why the real benefit of DAPT is front-loaded into the first 10–21 days.
How CHANCE, POINT, THALES, and meta-analyses sharpen the message: short-term DAPT cuts early recurrence; longer DAPT mainly buys bleeding.
Why most patients should land on ~21 days of DAPT, then SAPT indefinitely, and when 30–90 days might still make sense (e.g., intracranial stenosis, stenting protocols).
We also spell out when NOT to use DAPT:
Moderate–severe stroke with big infarcts and hemorrhagic risk
Cardioembolic stroke (AF, LV thrombus, valvular disease) where anticoagulation wins
Lacunar stroke, where SPS3 showed more bleeding without benefit
Patients with high bleeding risk or prior GI bleed, thrombocytopenia, or hemorrhagic transformation
ESUS and other gray zones where DAPT has no proven upside.
Finally, we zoom out to long-term secondary prevention:
Choosing between aspirin, clopidogrel, and aspirin–dipyridamole
Why clopidogrel often has the best net clinical profile (similar efficacy, less major bleeding)
How to build a stroke unit habit: NIHSS + ABCD² on arrival, early mechanism workup, tight DAPT stop dates, and defaulting back to SAPT instead of “set-and-forget” dual therapy.
If you’ve ever wondered “Should this patient be on DAPT, for how long, and what am I risking?” this episode gives you a crisp, evidence-based playbook you can use on your next stroke admission.

In this episode of Hospital Medicine Unplugged, we hit the brakes on routine bridging—who actually needs LMWH/UFH when you stop warfarin, and who is safer with no bridge at all?
We start by nailing the definition: bridging = temporarily swapping a long-acting oral anticoagulant (usually warfarin) for short-acting heparin (UFH/LMWH) during interruptions for procedures or bleeding. Then we zoom out to the core tension: tiny peri-procedural thromboembolic risk vs a 3–4× jump in major bleeding with bridging.
We walk through thromboembolic risk stratification—AF with CHA₂DS₂-VASc, recent VTE timing, mechanical valves, and severe thrombophilia—and pair it with procedure and patient bleeding risk (neurosurgery vs dental work, HAS-BLED factors, renal/liver disease, prior bleeds).
Then comes the evidence gut-punch:
BRIDGE: in AF on warfarin, no reduction in thromboembolism, but major bleeding triples with LMWH bridging.
Meta-analyses: no thrombotic benefit, big bleeding signal across mixed AF/VTE/mechanical valve cohorts.
PAUSE & DOAC data: rapid onset/offset means DOACs almost never need bridging.
From there we carve out the true bridging exceptions—the “maybe yes” group:• Mechanical mitral or older-generation mechanical valves• Very recent (<3 months) VTE or stroke/systemic embolism• Severe thrombophilia or high-risk cancer-associated VTE
Everywhere else, guidelines increasingly say: “Don’t bridge.” Most AF, remote VTE, bileaflet mechanical AVR without extra risk factors, and all DOAC-treated patients go down a simple interrupt-and-restart pathway instead of heparin drips and syringes.
We close with a practical, ward-ready playbook:• Step 1: Classify thromboembolic risk (AF/VTE/valve).• Step 2: Classify procedure + patient bleeding risk.• Step 3: If DOAC → timed hold based on drug + kidney function, no bridge.• Step 4: If warfarin and truly very high thrombotic risk → consider LMWH/UFH, but delay/avoid post-op therapeutic dosing when bleeding risk is high.• Step 5: Use prophylactic-dose LMWH as VTE prophylaxis, not as a stealth “mini-bridge.”
By the end, you’ll have a clean mental algorithm for “bridge vs no bridge” that lines up with ACCP, AHA/ACC, and AF guidelines—less bleeding, same stroke protection, and far fewer unnecessary heparin shots.